<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03019419</url>
  </required_header>
  <id_info>
    <org_study_id>A2016-J000-001</org_study_id>
    <nct_id>NCT03019419</nct_id>
  </id_info>
  <brief_title>Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS): A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tokyo Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tokyo Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety and the efficacy of perampanel in patients with sporadic&#xD;
      amyotrophic lateral sclerosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the effect of peramanel for 48 weeks on progression of disease in subjects with&#xD;
      ALS, as measured by ALS Functional Rating Scale-Revised (ALSFRS-R)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 24, 2017</start_date>
  <completion_date type="Actual">December 23, 2020</completion_date>
  <primary_completion_date type="Actual">December 23, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ALS Functional rating scale</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in ALS Functional rating scale</measure>
    <time_frame>12, 24, 36, and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manual Muscle Test</measure>
    <time_frame>12, 24, 36, and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent-predicted forced vital capacity</measure>
    <time_frame>12, 24, 36, and 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>ALS</condition>
  <arm_group>
    <arm_group_label>Perampanel 4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily 4mg of perampanel with dose-escalation tolerable from 2mg to 4mg for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Perampanel 8mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily 8mg of perampanel with dose-escalation tolerable from 2mg to 8mg for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once daily placebo for control for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perampanel</intervention_name>
    <description>4mg/d or 8mg/d</description>
    <arm_group_label>Perampanel 4mg</arm_group_label>
    <arm_group_label>Perampanel 8mg</arm_group_label>
    <other_name>non-competitive AMAP antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        [Eligibility Criteria for Interim Registration]&#xD;
&#xD;
          -  Patients who are able to submit written informed consent. If patients are duly capable&#xD;
             of study consent but are unable to sign by themselves due to aggravation of disease&#xD;
             condition, written informed consent can be obtained from a legally authorized&#xD;
             representative who can sign on behalf of the patients after confirming the patients'&#xD;
             agreement to study participation.&#xD;
&#xD;
          -  Patients who are male or female aged 40 years to 78 years at the time of obtaining&#xD;
             informed consent&#xD;
&#xD;
          -  Patients who have clinically definite ALS, clinically probable ALS, or clinically&#xD;
             probable-laboratory supported ALS as specified in the revised El Escorial Airlie House&#xD;
             diagnostic criteria.&#xD;
&#xD;
          -  The sum of the 3 respiratory items of the ALSFRS-R must total 12 points or more&#xD;
&#xD;
          -  Patients within 2-year elapsed time period from disease onset at the time of obtaining&#xD;
             informed consent&#xD;
&#xD;
          -  Patients who can visit study site for out-patient treatment&#xD;
&#xD;
        [Eligibility Criteria for Registration]&#xD;
&#xD;
        Subjects who meet the following criteria in addition to the inclusion criteria for the&#xD;
        interim registration&#xD;
&#xD;
          -  The progression on score of ALSFRS-R during 12 weeks of observation period must be&#xD;
             between -2 and -5&#xD;
&#xD;
          -  Patients who has not initiated newly introduced riluzole therapy after starting the&#xD;
             observation period. Or those who has not received dose escalation or resumed&#xD;
             administration of riluzole therapy after previous down titration or discontinuation&#xD;
&#xD;
          -  Patients who has not initiated newly introduced edaravone therapy after starting the&#xD;
             observation period&#xD;
&#xD;
          -  Patients who are judged to be eligible for continuation of the study by the&#xD;
             investigators&#xD;
&#xD;
        [Exclusion Criteria]&#xD;
&#xD;
          -  Patients who underwent tracheostomy.&#xD;
&#xD;
          -  Patients who experienced non-invasive positive pressure ventilation.&#xD;
&#xD;
          -  Patients whose percent-predicted forced vital capacity (%FVC) is â‰¤80%.&#xD;
&#xD;
          -  Patients with progressive bulbar palsy type.&#xD;
&#xD;
          -  Patients with cognitive impairment, severe disease in the renal, cardiovascular, or&#xD;
             hematological system.&#xD;
&#xD;
          -  Patients with hepatic disease.&#xD;
&#xD;
          -  Patients with malignant tumor.&#xD;
&#xD;
          -  Pregnant women or women with a possibility of becoming pregnant.&#xD;
&#xD;
          -  Patients who participated in another clinical study within 12 weeks before starting&#xD;
             the observation period.&#xD;
&#xD;
          -  Patients who has initiated perampanel therapy in the past or at present.&#xD;
&#xD;
          -  Patients who are judged to be ineligible for study entry by the investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomohiro Haga</last_name>
    <role>Study Director</role>
    <affiliation>The University of Tokyo Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kitasato University East Hospital</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Saishunso National Hospital</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shiga University of Medical Science Hospital</name>
      <address>
        <city>Shiga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Neurological Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tsukuba Hospital</name>
      <address>
        <city>Tsukuba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamaguchi University Hospital</name>
      <address>
        <city>Yamaguchi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 10, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2017</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sporadic ALS</keyword>
  <keyword>perampanel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

